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Abstract
Background: UK deaths due to chronic liver diseases such as cirrhosis have quadrupled over the last 40 years, making
this condition now the third most common cause of premature death. Most patients with advanced cirrhosis (end-stage
liver disease [ESLD]) develop ascites. This is often managed with diuretics, but if refractory, then the fluid is drained from
the peritoneal cavity every 10–14 days by large volume paracentesis (LVP), a procedure requiring hospital admissions. As
the life expectancy of patients with ESLD and refractory ascites (if ineligible for liver transplantation) is on average≤
6 months, frequent hospital visits are inappropriate from a palliative perspective. One alternative is long-term abdominal
drains (LTADs), used successfully in patients whose ascites is due to malignancy. Although inserted in hospital, these
drains allow ascites management outside of a hospital setting. LTADs have not been formally evaluated in patients with
refractory ascites due to ESLD.
Methods/design: Due to uncertainty about appropriate outcome measures and whether patients with ESLD would wish
or be able to participate in a study, a feasibility randomised controlled trial (RCT) was designed. Patients were consulted
on trial design. We plan to recruit 48 patients with refractory ascites and randomise them (1:1) to either (1) LTAD or (2)
current standard of care (LVP) for 12 weeks. Outcomes of interest include acceptability of the LTAD to patients, carers and
healthcare professionals as well as recruitment and retention rates. The Integrated Palliative care Outcome Scale, the Short
Form Liver Disease Quality of Life questionnaire, the EuroQol 5 dimensions instrument and carer-reported (Zarit Burden
Interview) outcomes will also be assessed. Preliminary data on cost-effectiveness will be collected, and patients and
healthcare professionals will be interviewed about their experience of the trial with a view to identifying barriers to
recruitment.
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Discussion: LTADs could potentially improve end-of-life care in patients with refractory ascites due to ESLD by improving
symptom control, reducing hospital visits and enabling some self-management. Our trial is designed to see if such patients
can be recruited, as well as to inform the design of a subsequent definitive trial.
Trial registration: ISRCTN, ISRCTN30697116. Registered on 7 October 2015.
Keywords: Ascitic fluid, End-stage liver disease, Paracentesis, Permanent indwelling peritoneal catheter, Palliative care,
Healthrelated quality of life, Quality-adjusted life years, Healthcare economics
Background
UK deaths due to chronic liver disease such as cirrhosis
have quadrupled over the last 40 years, making this condi-
tion the third most common cause of premature death
[1]. Ascites — an abnormal accumulation of fluid in the
peritoneal cavity — is present in up to 90% of patients
with advanced cirrhosis [2, 3], resulting in frequent hospi-
talisations due to debilitating episodes of pain and breath-
lessness. In the early stages, this condition can be
managed using diuretic therapy, but as the condition pro-
gresses (end-stage liver disease [ESLD]) the ascites be-
comes unresponsive to medical treatment. In the absence
of liver transplantation, a diagnosis of refractory ascites
confers a median life expectancy of ≤6 months [3–5].
End-of-life care in patients with ESLD and refractory ascites
has not been a research priority. More than 70% of patients
with ESLD die in hospital [6], a figure substantially — and in
our view unacceptably— higher than that of 40% for patients
with terminal cancer [7]. The most common palliative man-
agement for refractory ascites due to ESLD is large volume
paracentesis (LVP), performed every 10–14 days [3]. This in-
volves a costly 24–48 h hospital admission, insertion of a tem-
porary abdominal drain and removal of up to 15 L of ascitic
fluid over 4–6 h. There is simultaneous administration of
intravenous 4.5% or 20% (w/v) human albumin solution, 8–
10 g per 1 L of ascitic fluid removed [3]. Consequently, pa-
tients often delay the hospital visits until their ascites is tense
and painful [8], thus reducing their quality of life (QOL) [9].
Individuals with refractory ascites often have contraindica-
tions to alternative invasive procedures such as the transjugu-
lar intrahepatic portosystemic shunt (TIPS) [10] and/or the
automated low-flow ascites (ALFA) pump [11].
In this feasibility randomised controlled trial (RCT) we
will investigate the use of a simple and less invasive device,
the long-term abdominal drain (LTAD), in patients with re-
fractory ascites due to ESLD. This technique involves pla-
cing a tunnelled drain through the abdominal wall, with
ultrasound guidance, and with the patient under local anaes-
thetic. Once the drain is in place, the patient’s ascites can be
drained in the patient’s usual place of residence. Community
nurses or (where willing) carers can then remove smaller
volumes (1–2 L) of ascitic fluid in about 5–10 min, usually
two to three times a week dependent on patient preference.
These devices have been extensively utilised in patients
whose ascites is due to advanced malignancy, and they have
been shown to be both clinically effective and cost-effective.
They have low complication rates and offer improved QOL
[12, 13] (Mullan D, Laasch H-U, Jacob AHH:Tunnelled in-
traperitoneal catheters in the management of malignant as-
cites: complications and cost implications [2012],
unpublished). In terms of palliative care in refractory ascites
due to ESLD, there may be additional benefits, including the
involvement of patients and carers in the management of
this condition; reduced complications through the regular
removal of smaller volumes of fluid; and, importantly, re-
duced stigma associated with hospital-based LVP (voiced to
us as a concern by service users).
Given the relative success of these devices in patients
with ascites due to malignancy, there is a clear need for an
RCT in ESLD and refractory ascites comparing the use of
palliative LTADs to current standard of care (LVP), with
end-of-life QOL and cost-effectiveness as major out-
comes. LTADs have not been specifically assessed in pa-
tients with ESLD because of the potentially increased risks
of bleeding (due to coagulopathy) [14] and infections, spe-
cifically spontaneous bacterial peritonitis [15, 16].
There are additional concerns related to this specific pa-
tient group. We do not know whether such individuals
would be able or even willing to participate in an RCT, given
their potentially higher prevalence of alcohol and substance
misuse and other psychosocial issues. Similarly, there is un-
certainty as to the most appropriate assessment tools and
outcome measures. Finally, given the complex end-of-life
care needs of this cohort, concerns remain to patients,
carers and healthcare professionals (HCPs) over a strategy
that moves care away from the hospital to the community.
To address these issues we have designed a feasibility study
to inform the development of a subsequent definitive RCT.
Methods/design
Aim, design and setting of the study
The aim of this study is to assess the feasibility of conduct-
ing a future RCT of the safety, clinical effectiveness and
cost-effectiveness of refractory ascites management using
the LTAD against current standard of care (LVP) in patients
with ESLD when liver transplant is not an option. This
document is based on v6.0 of the protocol (13 October
2017). This multicentre trial has been designed in
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accordance with phase 2 of the Medical Research Council
(MRC) Complex Interventions Framework [17] and the
Method Of Researching End of Life Care guidance (MORE-
Care) [18].
This feasibility RCT is being conducted both at a hospital
(the Royal Sussex County Hospital [RSCH], Brighton, Sus-
sex, UK and the Princess Royal Hospital [PRH], Hayward’s
Heath, Sussex, UK, both part of the Brighton and Sussex
University Hospital [BSUH] National Health Service [NHS]
Trust; Worthing Hospital, Worthing, Sussex, UK [Western
Sussex NHS Foundation Trust], Plymouth Hospitals NHS
Trust, Plymouth, UK, Blackpool Victoria Hospital, Black-
pool, UK [Blackpool Hospitals NHS Foundation Trust] and
Southampton General Hospital, Southampton, UK [Univer-
sity Hospital Southampton NHS Foundation Trust]) and in
a community setting (The Sussex Community Trust).
Those randomised to the LTAD will be followed up in the
community. This 3-year study is planned to run from Sep-
tember 2015 until September 2018.
Characteristics of participants
Patients will be identified from acute medical units, out-
patients and gastroenterology and hepatology wards.
They will be approached for the study at the participat-
ing centres by the research team after having been iden-
tified by the local medical team as being potentially
eligible.
Inclusion criteria
The inclusion criteria are as follows:
1. Age ≥ 18 years, with no upper age limit
2. Untreatable (refractory) ascites defined as:
(a) Ascites that is unresponsive to fluid and sodium
restriction and high-dose diuretic treatment
(spironolactone 400 mg/day and/or furosemide
160 mg/day) and/or intolerance of diuretics [19, 20]
(b) Ascites that recurs rapidly after LVP (requiring
one or more LVP/month).
3. Child-Pugh score [21] of ≥ 9 unless specifically
decided by the medical team that they are to
receive only palliative treatment
4. Registered with a general practitioner (GP) in the
Community Trusts serving the participating centres
5. Ability to speak, read and understand English
6. Capacity to give written informed consent as
assessed by using a Capacity to Consent Checklist
(see Additional file 1)
Exclusion criteria
The exclusion criteria are as follows:
1. Loculated or chylous ascites
2. Presence of > grade 1 hepatic encephalopathy
(specified by West Haven Criteria [22])
3. Evidence of active infection, which in the
Investigator’s opinion would preclude insertion of
an LTAD, e.g. bacterial peritonitis. Such patients
could be reconsidered for inclusion in the trial if
infection has been successfully treated
4. Eligible for liver transplantation, in the opinion of
the hepatology multidisciplinary team (MDT) and
according to national guidelines [23]
5. Psychosocial issues which, in the medical team’s
opinion, would preclude engagement with the trial,
such as posing a risk to the safety of oneself or the
research team
As this is a feasibility study, we will not specifically ex-
clude patients based on abnormal haemostasis measure-
ments. Consistent with local practice, those individuals
with a platelet count of < 50 × 109 and/or an international
normalised ratio (INR) of > 1.7 will be given blood and/or
clotting products prior to receiving an LTAD or LVP.
Potential participants can be considered for inclusion
in this trial even if they are currently participating in an-
other research study, as long as their medical team are
confident that participation in the current trial would be
logistically feasible and not unduly onerous for the
participants.
While we would prefer that potential carers/consultees
are identified for each participant, their absence will not
preclude study participation.
Consent
Suitable participants will be identified by the usual med-
ical teams. A research team member (to include Chief
Investigator [CI], co-investigators, Principal Investigators
[PIs], nurse and research fellow) will provide patient in-
formation sheets (PISs) to potential research participants
and give an explanation about the study including ascites
management. Patients will be provided at least 48 h to
read the PIS. If willing, consent will be obtained in hos-
pital by a research team member. If the research team is
the usual medical team, to avoid any potential conflict of
interest, potential participants will be discussed at the
weekly liver multidisciplinary meeting (MDM). Capacity
to give informed consent will be carefully assessed (see
inclusion criteria). In the event that capacity is lost dur-
ing the trial, the participant’s nominated consultee will
be approached to determine whether the participant
should continue in the study. If a consultee has not been
nominated or is unavailable, then the participant’s usual
medical consultant (independent from the research
team) will be consulted to decide whether it is in the
participant’s best interests to continue in the study.
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Randomisation
Patients who fulfil the inclusion and exclusion criteria
and give written informed consent to participate in this
trial will be randomised on a 1:1 basis to either Group 1:
LTAD or Group 2: LVP (current standard of care). The
allocations will be made by minimising on (1) centre, (2)
Child-Pugh score and (3) gender. No stratification will
be utilised. Minimisation will be implemented using an
independent system hosted at King’s Clinical Trials Unit
(KCTU). Patients will be enrolled by the research team
member, who will log into the web-based system and
enter patient ID number, recruiting site, gender and
Child-Pugh score. The system will automatically gener-
ate a confirmation email informing the research team of
the outcome of allocation.
Patients will be followed up for 12 weeks. With the
participants’ agreement we will inform their GPs about
their participation in the trial.
Interventions
Group 1: LTAD
There are two LTADs currently available in the UK: the
PleurX™ (UK Medical Ltd., Basingstoke, UK [24]) and
the Rocket® (Rocket Medical, Watford, UK [25]). We
have chosen to use the Rocket device (Fig. 1) [25] pri-
marily because our local clinicians and community nurs-
ing teams are already familiar with it. Rocket Medical
already has an established training and support
programme for local community nurses and care homes.
In addition, our earlier experience [26] suggests that the
Rocket devices are easier to insert than the PleurX™ de-
vices and that they require less expensive consumables
that can currently be prescribed by community
practitioners.
Procedure for insertion of LTAD
Insertion of the LTAD will be performed in hospital in a
side room, using bedside ultrasound guidance. Insertion
will only be performed if, within the week leading up to
planned LTAD insertion, haemostatic function (including
INR and platelet count) has been checked and blood prod-
ucts administered as necessary. Where INR is > 1.7, pa-
tients will receive up to two volumes of fresh frozen plasma
(FFP), transfused according to patient weight and INR, im-
mediately prior to drain insertion. Where the platelet count
is ≤ 50 × 109, patients will be given one to two pools of
platelets immediately prior to insertion of the drain.
To ensure consistency, it would be ideal that all
LTADs are inserted at one site (RSCH), but if this is not
possible due to patient preference or logistic issues, they
will be inserted at local sites, usually by an interventional
radiologist.
The Rocket® LTAD will be inserted using a combination
of tunnelled and Seldinger technique as stated in the
Rocket® information sheet [25]. After confirming the loca-
tion of the insertion site using bedside ultrasound and skin
preparation with Chloraprep™ (chlorhexidine gluconate
and isopropyl alcohol), a local anaesthetic (up to 10 ml 1%
or 2% lidocaine) will be administered at the incision site
and along the proposed tunnel tract. A small incision is
made where the catheter will enter the abdominal cavity.
The introducer needle will be inserted through the inci-
sion into the peritoneal cavity and a guide wire is passed
through the needle, which will then be removed. A second
incision (exit site) will be made approximately 5 cm med-
ial from the first, where the catheter will exit the tunnel.
The catheter will be tunnelled from exit site incision to
the first incision site with the tunneller, making sure that
the cuff is midway between the first and second incision
sites. A split-sheath dilator will then be passed over the
guide wire, and the inner dilator and guide wire removed,
leaving the split sheath in situ.
The tunneller is then removed from the catheter,
which is then passed through the split sheath, separating
the split sheath and ensuring that all of the catheter is
contained within the peritoneum. The last piece of the
split sheath is then removed. The catheter is then ad-
justed along the tunnel, so the cuff moves towards the
exit site, ensuring that any kinks are removed from the
catheter. Finally, both incision sites will be sutured
(avoiding the catheter) and a dressing applied.
Participants will receive antibiotic prophylaxis (cipro-
floxacin 500 mg/day) or an equivalent antibiotic (if there
is a contraindication to ciprofloxacin), dependent on
local practice.
We will provide guidance to the participant and carer
(where present) on how to use the LTAD, based on the in-
formation previously supplied in the PIS. Participants will
also be given an information sheet provided by Rocket
Fig. 1 Rocket Medical Long-Term Abdominal Drain in situ [25]
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Medical [25]. Participants will be referred to their commu-
nity nursing service. A Rocket Medical discharge letter
will be sent to their GPs and the community nursing team.
Rocket Medical will also be informed so that they can or-
ganise any further support/training for patients, carers
and community nurses. In addition, we will arrange for
drainage bags to be delivered directly to the participant’s
usual place of residence on request by the community
nurses.
The community nurses will visit the participants in
their homes and either perform the drainage procedure
themselves or supervise the drainage of ascites. The fre-
quency of these visits will depend on the participant’s
ascites-related symptoms, but work in ascites due to ma-
lignancy [12, 27] indicates that two to three visits each
week are most commonly required, with approximately
1–2 L of ascites being drained each time. It is recom-
mended that the drainage frequency not exceed three
times per week. In the event that participants and/or
carers wish to perform self-drainage, they will be trained
to do so by the community nurse.
The Integrated Primary Care Team (IPCT) will closely
monitor trial participants allocated to the LTAD arm.
We expect that this will happen two to three times a
week if the community nurses are performing ascitic
fluid drainage.
For participants who live in a care home or move to a
care home (with or without nursing), the follow-up pro-
cedure would be the same as for patients who live at
home. In such cases we would seek approval from the
care home managers. For those requiring hospice care,
this would be a temporary stay, since hospices do not
generally provide long-term care. Again, permission will
be sought from the hospice team to visit the participants
for follow-up and only if such visits remain acceptable to
the participants.
Group 2 standard of care (LVP)
Participants randomised to LVP [3], the current standard
of care, will be admitted to hospital as either a
self-referral or via their GP, whichever is current local
practice. They will undergo LVP as clinically indicated.
LVP involves the insertion of a peritoneal drain for up to
6 h and removal of up to 15 L of ascites. If the total vol-
ume of fluid to be removed is > 5 L, intravenous 4.5% or
20% (w/v) human albumin solution, 8–10 g per 1 L of
ascitic fluid removed, will be administered [3].
As with Group 1, participants will receive antibiotic
prophylaxis (ciprofloxacin 500 mg once a day or an
equivalent antibiotic (if there is any contraindication to
ciprofloxacin), dependent on local practice).
For both groups there will be two weekly visits with a
research team member for questionnaire-based and clin-
ical assessments as well as routine clinical blood samples
(as discussed in subsequent sections). We anticipate that
these two weekly contacts will improve adherence to the
protocol.
Clinical follow-up
While participating in this trial, for no individual will
routine clinical care be modified or denied whether in
the community, primary care or hospital setting. This
will include symptomatic relief for pain (including use of
opioids), shortness of breath, confusion (hepatic enceph-
alopathy), jaundice or itching. Use of diuretics will be
permitted in both groups. As is the current standard of
care in patients with ESLD, the use of certain drugs (e.g.
non-steroidal anti-inflammatory drugs, aminoglycosides)
will be contraindicated [3].
Palliative care needs and concerns will be reassessed at
each visit for each participant using the Integrated Pal-
liative care Outcome Scale (IPOS) questionnaire [28]
(see subsequent sections). If a high level of specialist pal-
liative care need is identified (as defined within a distress
protocol standard operating procedure [SOP]), through
the IPOS questionnaire, a research team mini MDM (ei-
ther face-to-face or virtual) will be convened to agree on
the most appropriate way forward. As is standard clinical
practice, referrals to a specialist service by the usual
healthcare providers can also occur irrespective of any
trial assessments or advice. If that occurs, consistent
with standard practice, a referral is simultaneously made
to a community (district) nurse, if this was not already
done for another reason.
It may become necessary, after discussion with the CI
and the Trial Management Group (TMG), to remove the
LTAD. Reasons for this could include (1) patient request,
(2) serious adverse reaction (SAR) assessed by the CI as
being directly related to the LTAD and (3) significant de-
viation from the study protocol with potential for harm
(for example the participant not allowing community
nurses to enter residence to perform drainage).
The contact telephone numbers for key members of
the research team will be provided to the participants.
Out of hours, participants will be encouraged to contact
their GP or attend the accident and emergency depart-
ment of their local hospital, as per usual standard of
care.
Outcome measures
The objectives of this feasibility study therefore are to
explore:
 Properties of different outcome measures
(specifically health resource utilisation and QOL
instruments) to ascertain the most appropriate
primary outcome for the full trial and use the
chosen primary outcome measure to inform sample
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size calculations from estimates of the standard
deviations, for the full trial
 Resource implications of the LTAD compared to
standard of care (LVP), including a preliminary
assessment of cost-effectiveness to indicate whether
a full trial is worthwhile
 The number of eligible patients
 The extent of HCP support in identifying possible
participants
 Symptom burden in patients with ESLD and
refractory ascites
 Informal carer/family perceived burden (if appropriate)
 Whether patients are willing to be randomised to
LTAD, rather than LVP
 Acceptability of and adherence to home ascites
drainage
 Attrition rates, including attrition due to death,
illness or other causes
 Complication rates inclduing peritonitis
 Willingness to participate in a qualitative interview
(optional)
 Acceptability of the LTAD to patients, carers and
clinical staff using qualitative methods (optional)
 Acceptability of questionnaires
We will therefore collect data on a range of candidate
primary outcome measures, including QOL and health
resource utilisation. The primary outcome measure(s)
for the definitive trial will be decided by the research
team, including service users, on review of the final ana-
lysis of this feasibility study.
Study success criteria
The study success will be based on the following criteria:
 The percentage of study period time in hospital for the
LTAD group is < 50% of that for the LVP group (where
the study period time is the number of days from the
date of LTAD insertion to the end of the study period
or the patient’s death (whichever is earliest); time spent
in hospital is the number of bed days used).
 The attrition rate is not > 50%.
 There is < 10% overall rate of LTAD removal due to
one or more of the following complications:
peritonitis, failed insertion, bleeding and blockage.
 Each patient has completed 80% of the
questionnaires and qualitative interviews.
Data collection
Data will be collected on an electronic case report form
(eCRF), using the MACRO electronic data capture sys-
tem provided by KCTU and hosted on the King’s Col-
lege London (KCL) server. The system is compliant with
Good Clinical Practice (GCP), with a full audit trail and
formal database lock functionality.
Figure 2 shows the participant timeline/study flow chart.
Schedule of assessments
The research team member will visit participants at
home every 2 weeks for questionnaire-based and clinical
assessments (see the subsequent section) as well as col-
lection of routine clinical blood samples. The amount
and frequency of drainage and other pertinent observa-
tions will be recorded by community nurses in a formal
study diary, as is the case when the LTAD is used in pa-
tients with ascites due to malignancy. The research team
member will train and advise the community nurses and
participants on data collection to reduce the possibility
of missing data. See Fig. 2 and the Standard Protocol
Items: Recommendations for Interventional Trials
(SPIRIT) schedule (Fig. 3).
Questionnaire-based assessments
The questionnaire-based assessments will be per-
formed by the research team member and, depending
on patient preference, will be done either face to face
at the patient’s home or via telephone (within 3 days
of the research team member visit). The research
team member will follow guidance in the lone worker
policy when conducting home/usual place of care
visits.
We have selected questionnaires validated with our
population group (e.g. palliative care patients and
those with ESLD). Some, like the IPOS [28] (see the
following section), are short, relatively brief to
complete and have a proxy version if a patient loses
capacity during the study. As this is a feasibility
study, we will explore the acceptability of the mea-
sures used. We will pilot the patient questionnaires
comprising the proposed measures with the first eight
patients to explore and assess patient fatigue and time
taken for completion. We will review the pilot find-
ings and amend the patient questionnaire schedule if
indicated, submitting the required Research Ethics
Committee (REC) amendment for all proposed
changes. The research team member will assist the
participants in completion of the questionnaires if
needed and if specifically requested by the participant.
If participants are too unwell, the questionnaires can
be completed by proxy by the carers, to reduce both
the participant burden as well as the risk of missing
data. Additionally, for those patients allocated to the
LVP group, if the hospital visits coincide with ques-
tionnaire assessments, the assessments can be done at
that point in hospital.
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Symptom distress and concerns
The IPOS [28–30] combines the Palliative care Outcome
Scale (POS) and POS-S (POS with symptom list). These
are measures frequently used in palliative care research
and clinical practice [28–32]. They are validated for clin-
ical practice, audit and research and can be used in any
setting. The POS-S captures physical symptom specific in-
formation, and “other” symptoms specific to liver disease/
ascites can be added, e.g. abdominal bloating. A SOP will
be implemented when clinical and/or risk of harm issues
are identified to ensure timely assessment by their usual
healthcare providers and/or referral to a specialist pallia-
tive service depending on needs identified.
A staff version of the IPOS will be used in case partici-
pants are unable to complete the questionnaire. The IPOS
will be assessed at baseline and two weekly and takes less
than 10 min to complete (a total of 10 questions).
Quality of life
QOL will be assessed using the Short Form Liver Dis-
ease Quality of Life (SF-LDQOL) [33, 34], a reliable and
valid measure of health-related QOL in patients with ad-
vanced liver disease awaiting transplant, incorporating a
core QOL assessment and disease targeted items. As
specific QOL assessment tools are lacking in cirrhosis,
the SF-LDQOL is the most appropriate option and was
selected after service user involvement. The original
SF-LDQOL questionnaire has 43 questions, though the
questions from 26 onwards are for the purposes of valid-
ating the questionnaire and not specific to the
SF-LDQOL itself [33, 34]. The authors have provided a
scoring algorithm that includes only the first 25 ques-
tions; therefore, only these questions will be used. This
questionnaire takes about 15 min to complete and will
be assessed at baseline and four weekly.
Community 
nurses informed 
Rocket Medical 
informed 
Patient with end stage cirrhosis and ascites
Eligibility and Consent
Randomisation
LTAD Group 1 LVP Group 2
Drain inserted in hospital
Training provided to participant
Repeated drainage in hospital 
as clinically indicated
Drainage of fluid dependant on 
symptoms by community nurses or if 
willing by participant/carers
For both groups
- Antibiotic prophylaxis
- Community Specialist Palliative Care Team referral if clinically indicated (accompanied by community 
IPCT nursing referral if not already in place)
- Baseline and two weekly symptom (IPOS) assessment
- Baseline and two weekly service use assessment (ACHR)
- Hospital service use assessment (in house questionnaire) at end of study
- Baseline and four weekly QOL (SFLDQOL) and health outcome assessment 
- Baseline and four weekly carer assessment (ZBI-12)
- Baseline and four weekly health outcomes (EQ-5D-5L)
- Standard of care bloods every two weeks 
- 20 ml of blood for research purpose
Fig. 2 Participant timeline
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Health economics outcome
There are opposing views on the use of the EuroQol 5
dimensions (EQ-5D) as a composite measure of
quality-adjusted life years (QALYs) in palliative care [18].
However, it is the most widely used indicator, and until valid
alternatives are available, we have elected to assess the 5-level
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Timepoint (weeks) - t0 t2 t4 t6 t8 t10 t12
Capacity check
Informed Consent1
Demographics 
Medical History
Eligibility according to inclusion/exclusion criteria
Routine liver ultrasound2
Research blood sample for storage 3
Liver screen blood tests4
Blood/urine culture, ascitic tap, urine dipstick 5
Randomisation6
Alcohol and substance misuse assessment
Liver disease scores 
Routine haematology and biochemistry
Diagnostic paracentesis7
Liver disease assessment and history
Adverse event review
Concomitant medication review
Examination and vital signs8
LTAD insertion (or LVP)
Drainage assessment (both LTAD and LVP)
Questionnaires: IPOS, AHCR
Questionnaires: SF-LDQOL, EQ5D-5L, ZBI-12 
Questionnaire: Hospital service use
Qualitative interviews Phase 1 Phase 2
Legend for SPIRIT Schedule
1. Informed consent can be given prior to the screening visit, but must be confirmed at  
the screening visit.
2. Unless previous imaging (CT, MRI or ultrasound) is available within the previous six
months.
3. 20 ml of blood will be taken at baseline for future ethically approved research, (10 ml 
saved as serum, and 10ml as whole blood as per laboratory SOP).
4. HBsAg, HCV antibody, HIV antibody, ANA (antinuclear antibody), AMA (Anti-
mitochondrial anti-bodies), SMA (smooth muscle antibody), LKM (kidney microsomal 
antibody), serum ferritin, serum copper, serum caeruloplasmin, serum alpha-1 
antitrypsin, fasting serum total cholesterol, triglycerides, high density lipoprotein (HDL) 
cholesterol, total cholesterol:HDL ratio and low density lipoprotein (LDL) cholesterol (if 
not done in the previous three months).
5. If not performed within the last 48 hours or 14 days prior to baseline visit.
6. Randomisation can be done up to 14 days prior to the baseline visit.
7. If not performed within the last two (screening visit) or seven days (baseline visit). For 
subsequent visits this will be done if clinically indicated (Group 1: LTAD) or, in the 
case of Group 2 (LVP), at each visit.
8. Temperature, blood pressure and pulse; height and weight at baseline visit only.
Fig. 3 SPIRIT schedule
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version (EQ-5D-5 L) [35] (at baseline and four weekly) in this
feasibility study for its utility as an outcome. The EQ-5D-5 L
has six questions and will take about 5 min to complete.
Impact on carers
For those willing to participate, the Zarit Burden Inter-
view (ZBI-12) [36, 37] will be employed at baseline and
four weekly. The ZBI-12 measures family/informal carer
appraisal of the impact of caregiving. It has 12 items, is
easy to administer and it can be used in the hospital or
community setting, taking about 10 min to complete.
Service use assessment
For each arm of the feasibility study, a comprehensive
patient-level database of services used will be collated,
including all inpatient, outpatient, emergency, primary,
community, social and voluntary services, equipment
and supplies and assistance from family/informal carers.
For community and home-based services, a modified
version of the Ambulatory and Home Care Record
(AHCR) [38] will be used and administered by the re-
search team member at baseline and two weekly. The
carers will assist with this, especially if the participant is
too unwell. The AHCR, a standardised and comprehen-
sive framework and tool, measures resources used within
the end-of-life context from a societal perspective. This
approach gives equal consideration to costs borne by the
health system as well as those costs borne by care recipi-
ents and informal caregivers, such as family members
and friends. It will take about 20 min to complete.
Self-reported data will be verified and supplemented
(e.g. for supplies) with reference to nursing records. Data
on all hospital use will be gathered from hospital records
at the end of the study using a purposefully designed
in-house proforma. Service use will be converted to
costs using national sources [39] and National Health
Service (NHS) reference costs. Informal care will be val-
ued using replacement cost methods and applying the
tariff for community support workers.
A feasibility study gives us the opportunity to test can-
didate patient-reported outcome measures with the
intention of only taking the most useful measures
through to any definitive study. Survey fatigue was al-
ways a concern for the research team and our service
users, and the issue also arose during the Ethics Com-
mittee review process. Therefore, we had a safety check
to reassess survey fatigue after the first eight patients
were recruited. We have found no evidence of any prob-
lems so far; indeed some patients restate their willing-
ness to complete the questionnaires.
Qualitative interviews
Qualitative data will be collected as part of a concurrent
embedded strategy [40]. Interview themes will include an
exploration of experiences of recruitment, participation,
LTAD/LVP and end-of-life care; beliefs about the role and
value of the LTAD in refractory ascites; and practical steps
and barriers involved in undertaking the LTAD.
Twenty-eight optional interviews (with 20 participants
and 8 clinical key informants) will be undertaken by a
qualitative researcher, with additional support if needed.
Clinicians and research participants will be identified and
recruited via the research team member. Patient recruit-
ment will seek to reach a maximum diversity sample of
participants, i.e. interview participants with a wide range
of demographic characteristics, with purposive sampling
(if feasible), informed by the IPOS (given that the individ-
uals of this cohort are living with deteriorating health).
The research team member will invite patients to partici-
pate in the qualitative interview study and will seek per-
mission to pass contact details (normally telephone
number) to the qualitative researcher. The qualitative re-
searcher will contact participants to arrange a convenient
time for the interview. As life expectancy in refractory as-
cites due to ESLD is on average 6 months, the qualitative
interview methodology seeks to explore a wide range of
patient experiences, recognising that participant beliefs
and experiences may change across this period. Interviews
will, therefore, be divided into two phases:
Phase 1 (weeks 0–8) 12 patients (6 from each arm), 4
clinical staff
Phase 2 (weeks 9–12) 8 patients (4 from each arm), 4
clinical staff
In the event of inability to recruit new participants for
Phase 2 interviews, additional participants or repeat
interviews will be sought during Phase 1. Interviews with
key clinical staff will follow the same aims of patient
interviews and will be anonymous (i.e. key informants
will be asked to withhold patient identities).
Interviews will take place at participants’ homes or by
telephone according to participant preference and geo-
graphical location. Clinical staff will be interviewed at
their place of work or at a mutually convenient venue.
Consent will be taken from all participants, including
any carer requested by the participant to be present. For
telephone interviews, consent will be taken verbally and
recording will be started before telephone consent is
taken, so that the verbal consent can be recorded as a
separate file from the interview. Signed consent forms
will be kept for 5 years. Interview data will be tran-
scribed and the audio version deleted. The anonymised
transcription of the interview (including the verbal con-
sent) will be stored (labelled with patient study number).
To reduce participant burden, breaks will be allowed
during the interviews if requested by the participants,
and interviews will last between 20 and 60 min.
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Safety monitoring
A monitoring plan will be put in place and adhered to for
each research site (see Additional file 2). Monitoring visits
will be undertaken by the Brighton and Sussex Clinical
Trials Unit (BSCTU) on behalf of the Study Sponsor. The
study may be audited in line with the BSCTU or by the
Sponsor requirements. Audits will be conducted by
personnel independent from the research team.
Common Terminology Criteria for Adverse Events
(AEs) (CTCAE, version 4.03) [41] will be used when
assessing AE and serious adverse events (SAEs). As this
is a feasibility study, all AEs and SAEs will be recorded
in the source data and reported on the eCRF. Crucially,
only those SAEs that in the opinion of the CI are related
to the study intervention (LTAD) will be reported in an
expedited manner to the BSCTU.
This feasibility RCT is investigating the LTAD in a co-
hort with ESLD. By its very nature, this is a group with
high morbidity and mortality. Hence, in this patient
population, worsening of existing conditions, hospitalisa-
tions, acute illnesses and deaths are expected. These
events will be recorded in the eCRF but will not be re-
ported to the BSCTU or the REC.
Expected/unexpected unrelated AEs/SAEs will include
but not be limited to:
 Hepatic encephalopathy
 Gastrointestinal bleeding related to peptic
ulceration, hypertensive portal gastropathy or
varices
 Liver cancer and or its treatment
 Complications of gastroscopy (perforation, bleeding)
 Complications of LVP (circulatory and or electrolyte
disturbances, bleeding, bowel perforation, failed
drainage)
 Complications of drug treatment for cirrhosis
(lactulose, beta blockers, terlipressin, antibiotics,
diuretics)
 Death related to the liver disease; will include death
from liver failure, multiorgan failure, variceal
bleeding and sepsis
Expected serious adverse reactions (SARs)
If in the CI’s opinion a SAR is considered directly related
to the LTAD and is an expected SAR, then this will be
recorded on the eCRF and reported to the BSCTU im-
mediately following the Safety Reporting SOP. Expected
SARs will include the following (but only if they result
in hospitalisation):
 Failure of LTAD insertion
 Drain leakage or blockage
 Cellulitis
 Bleeding
 Pain at site of insertion not controlled by analgesia
 Spontaneous bacterial peritonitis
 Sepsis which in the opinion of the CI is directly
related to the LTAD
 Death which in the opinion of the CI is directly
related to the LTAD
Suspected unexpected, serious adverse reactions
(SUSARs)
This category will include all SARs that in the opinion of
the CI are directly related to the intervention and are
not listed as a known (expected) SAR. All SUSARs that
occur between insertion of the LTAD and 3 months post
insertion or death, whichever is earlier, will be recorded
on the eCRF and emailed/faxed to the BSCTU immedi-
ately, at least within 24 h of the research team becoming
aware in accordance with the BSCTU Safety Reporting
SOP. The REC will be notified of any SUSAR to the
study intervention by the BSCTU. For each SUSAR, all
relevant information will be collected, and the SUSAR
will be followed up until resolved or a final outcome
reached.
The CI will have direct and ultimate responsibility for
reviewing all reported SARs and SUSARs and will ensure
that the BSCTU reports these appropriately according to
the BSUH SOP on Safety Reporting in Non-Clinical
Trial of an Investigational Medicinal Product (CTIMP)
studies.
Data analysis
Statistical analysis
Guidelines for feasibility studies suggest that analysing
12 participants in each arm will provide an adequate
sample size with which to achieve our objectives [42].
However, since this is a cohort with a poor prognosis, at-
trition is likely to be high. In our pilot study of seven pa-
tients [26], survival post insertion ranged from 6 to
96 days (though the LTADs were inserted late in the dis-
ease trajectory). Due to the advanced disease stage of the
participants, we are assuming a 50% attrition. The sam-
ple size will therefore be increased to 24 participants in
each arm, i.e. a total recruitment target of 48 partici-
pants. This sample size will be adequate to inform the
research methods for a definitive phase 3 RCT.
Recruitment rate will be evaluated in terms of the pro-
portion of eligible patients who provide informed con-
sent. Attrition at all stages will be recorded, particularly
due to unwillingness or inability to manage the LTAD,
as this is an indication of acceptability. Data will be ana-
lysed on available cases in the groups to which they were
randomised. We will present these data as a flow chart.
The amount of missing data will be summarised for each
variable, but there will be no imputation. As this is a
feasibility study, stopping rules will not be defined.
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The flow of patients through the trial is depicted in
the Consolidated Standards of Reporting Trials (CON-
SORT) diagram (Fig. 4) [43].
Descriptive statistics will be used to summarise and
compare the quantitative outcome measures to include
(1) complication rates: failed insertion, drain leakage or
blockage, cellulitis, bleeding, pain at site of insertion not
controlled by analgesia, peritonitis, sepsis and death (the
latter two only if directly related to the LTAD), (2) symp-
toms: IPOS, QOL (SF-LDQOL, EQ-5D-5 L) [28, 33–35]
and (3) carer burden [36, 37] for each arm. Means and
standard deviations will be determined for normally dis-
tributed outcomes and medians and interquartile ranges
for skewed outcomes at the different time points and at
the end of the study. Analyses will use all available cases
following intention-to-treat principles. We will calculate
95% confidence intervals for parameter estimates as ap-
propriate. Prior to the analysis of the data, a detailed
statistical analysis plan will be written and signed off.
Health economics data analysis
The economic analysis will adopt the perspectives of the
health and social care systems.
Using the patient-level database assembled from par-
ticipant self-report and hospital and community nursing
records, the feasibility study will identify the main re-
source items for which comprehensive data collection
would be required in the main trial. Interactions
between ascites management and other palliative care
services will be explored. In particular, community nurse
visits in both groups will be monitored, so extra visits
required for the LTAD, compared to normal care, which
was a major source of uncertainty in the earlier model-
ling study, can be identified [13]. The group mean total
costs of services used in ascites management will be
compared between LTAD and LVP.
The properties of the main clinical outcomes (IPOS,
SF-LDQOL, EQ-5D-5 L) [28, 33–35] and the number of
hospital days will be investigated to assess their value as
measures of effectiveness for the definitive trial so that a
primary outcome can be determined. Data on QALYs from
EQ-5D-5 L [35] will be investigated for possible use in the
economic evaluation. A preliminary cost-effectiveness ana-
lysis will be undertaken to determine the likely advantage
of conducting a full trial [44]. A sensitivity analysis will be
performed by varying the key cost drivers, such as the num-
ber of inpatient days and the cost of bed days.
Qualitative data analysis
If purposive sampling is not feasible, the proportion of
participants choosing to participate in qualitative inter-
views will be noted. Interviews will be audio recorded
and labelled using the same anonymous study number
as the intervention component of this study. The same
number will be used so that in the event of a participant
reporting a serious concern about his/her condition or
Fig. 4 Consort flow chart
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care, the qualitative researcher can raise this concern
with the patient’s clinician. In this unlikely event, the re-
searcher will inform the patient of the need to convey
this information to the clinician. The qualitative re-
searcher will have access to the clinical study data of the
individual if needed.
Thematic analysis supported by qualitative software
(NVivo) [45] will be used to extract overarching themes
from the interviews to capture patients’ experiences and
beliefs. Utilising the process of triangulation [46], the
findings of the qualitative arm will be used to inform the
quantitative results, particularly in the context of QOL
and experience of end-of-life care provision.
Data will be analysed in a blinded manner. However,
the research team members collecting information from
the patients will always be aware of their allocation since
a high level of scrutiny is necessary to ensure that there
are no safety events in the LTAD group. Our service
users were also insistent that participants not engage
with multiple members of the research team, further ex-
cluding blinded data collection.
Ancillary and post-trial care
At the end of the trial, participants will continue to be
assessed by their usual medical care team. Those allo-
cated to the LTAD arm will have the option, if they so
wish, to continue with the LTAD under care of their
usual consultant gastroenterologist/hepatologist.
Committees
Trial Management Group (TMG)
The TMG will comprise the CI, all co-investigators and
PIs, research fellow, trial manager, data manager and
statistician and will be chaired by the CI (SV).
The TMG will meet every month to:
1. Finalise trial-related materials
2. Oversee and co-ordinate the various aspects of the
project, so that the research completes on time and
on budget
3. Assess study progress to ensure that recruitment is
on target and on budget. If recruitment is below
that anticipated, then strategies to improve this will
be discussed
4. Assess adherence to protocol by reviewing protocol
deviation logs.
Data Safety Monitoring Committee (DSMC)
The DSMC will be an independent committee chaired
by Professor Guruprasad Aithal (Professor of Hepatol-
ogy, Nottingham University NHS trust) with two other
independent members, Professor Bobbie Farsides (Chair
of Medical Ethics at BSMS) and Professor Martin
Llewelyn (Professor in Infectious Diseases, BSMS and
Hon Consultant, BSUHT), as well as at least one service
user member. A study data report will be provided to
the DSMC by the trial manager every 10–12 months for
the first 2 years and then every 6 months for the last
year, in accordance with the Terms of Reference for the
Committee. The DSMC will meet as above to address
any safety concerns, review any ethical issues raised and
monitor adverse events. The DSMC will make recom-
mendations to the TMG as appropriate and has the
power to stop the trial if necessary. The DSMC will be
independent of the Study Sponsor. Details of the Inde-
pendent Data Monitoring Committee (IDMC) charter
can be obtained from trial.monitors@bsuh.nhs.uk.
Discussion
The impetus for the REduced Drainage Utreatable
Cirrhosis (REDUCe) trial was driven by our concerns
that patients with ESLD receive suboptimal end-of-life
care compared to those with other terminal conditions.
Most individuals with ESLD almost always die in
hospital [6] while receiving end-of-life care, even though
in many cases palliative care provided within the com-
munity would be more appropriate and compassionate.
Such an option is often not feasible due to the complex
end-of-life needs of patients with ESLD (including LVP)
and the fluctuating disease trajectory making it difficult
to define when a palliative phase has been reached [6,
47]. Most patients with ESLD develop ascites [2, 3], and
the management strategy in ESLD is thus often dictated
by this specific symptom. Our own data suggest that
approximately 40% of patients with ascites requiring
LVP can go on to develop refractory ascites [48]. This
condition has a major impact on the QOL in ESLD, due
to factors such as direct physical discomfort but also the
need for recurrent hospitalisation for LVP [3, 49].
We would argue that for many such individuals these
recurrent hospitalisations impair their QOL. A more ap-
propriate option would be to focus on holistic palliative
care in the community, based on discussions on future
wishes [49, 50]. This will require a multidisciplinary ap-
proach to the disease, reflected in the composition of
the REDUCe study team.
Consistent with the lack of research in this complex
cohort of individuals and therefore not unexpectedly, re-
cruitment to this trial has been challenging. We found
that clinicians who were not part of the study team were
often reluctant, particularly in younger patients, to diag-
nose ESLD and discuss the implications of a limited life
expectancy and purely palliative management. In some
instances prospective participants were only identified
late and unfortunately died before they could make an
informed decision about trial participation. The patients
themselves are often vulnerable and (in their opinion)
disenfranchised and stigmatised. Finally, setting up new
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sites for a study that spans both acute hospital and com-
munity settings, often without existing research collabo-
rations, has been difficult and time-consuming.
Conversely, we have already begun to note positive
changes in attitudes, beliefs and practice of HCP locally
and in the study sites. Simply by attempting to discuss
the REDUCe trial, we have seen a change in attitudes to-
wards symptom control and QOL as well as timely refer-
ral to palliative care. There is also increasing recognition
that patients should be able to be more involved in deci-
sions about their end-of-life care. This trial has raised
the local profile of these under-researched patients, with
wider recognition of the need for MDT communication
and collaboration. Specifically, many local hospitals now
discuss all patients with ESLD at a weekly liver MDM so
as to identify in a timely manner those who are entering
the palliative phase of their disease. This has undoubt-
edly driven the improvement in recruitment. The Na-
tional Institute for Health Research (NIHR),
acknowledging this and the potential of this study to re-
sult in a paradigm shift in end-of-life care in ESLD, has
granted a funded extension for a year.
Trial status
The trial is now open, with 36 patients recruited as of
May 2018. Funded extension was obtained May 2017.
Additional files
Additional file 1: REDUCe Study. (PDF 69 kb)
Additional file 2: Monitoring plan. (PDF 395 kb)
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